A phase I clinical study of the combination of DS-1205c with Gefitinib for metastatic or unresectable EGFR-mutant NSCLC (NCT03599518) demonstrated no serious adverse events directly related to DS-1205c [86]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.